GWQ ServicePlus AG
Germany · 179 open tenders · 2,671 documented awards
Current tenders
Germany – Pharmaceuticals – Conclusion of non-exclusive rebate agreement pursuant to § 130a (8) SGB V for the active ingredient Guselkumab
Deadline 10 Nov · 82 days left
Germany – Medicines – Conclusion of non-exclusive rebate agreements pursuant to § 130 a para. 8 SGB V from 01.07.2025
Deadline 10 Nov · 82 days left
Conclusion of non-exclusive discount agreement pursuant to § 130a (8) SGB V for the active ingredient guselkumab
Deadline 10 Nov · 82 days left
Conclusion of non-exclusive discount agreements pursuant to § 130 a para. 8 SGB V with the active ingredient Adalimumab
Deadline 10 Nov · 82 days left
Conclusion of non-exclusive discount agreements pursuant to § 130 a para. 8 SGB V with the active ingredient Doxylamine 6.96 mg / Pyridoxin 8.23 mg HVW (Cariban)
Deadline 10 Nov · 82 days left
Germany – Medicines – Conclusion of non-exclusive rebate agreements pursuant to § 130 a para. 8 SGB V with the active substance Oxybutynin in the pharmaceutical form PFT
Deadline 10 Nov · 82 days left
Conclusion of non-exclusive rebate agreements pursuant to § 130a (8) SGB V for biosimilar active substance contracts
Deadline 10 Nov · 82 days left
Germany – Pharmaceuticals – Conclusion of non-exclusive rebate agreements pursuant to § 130 a para. 8 SGB V with the active ingredient Doxylamine 6.96 mg / Pyridoxin 8.23 mg HVW (Cariban)
Deadline 10 Nov · 82 days left
Conclusion of non-exclusive discount agreements pursuant to § 130 a para. 8 SGB V from 01.03.2025 to 31.12.2026
Deadline 10 Nov · 82 days left
Germany – Pharmaceuticals – Conclusion of non-exclusive discount agreements pursuant to § 130 a subsection 8 SGB V for the period 01.01.2025 - 31.12.2026
Deadline 10 Nov · 82 days left
Germany – Pharmaceuticals – Conclusion of non-exclusive rebate agreements pursuant to § 130 a para. 8 SGB V from 01.07.2025
Deadline 10 Nov · 82 days left
Germany – Pharmaceuticals – Conclusion of non-exclusive rebate agreements pursuant to § 130 a para. 8 SGB V with the active ingredient combination Adapalene + Benzoyl Peroxide
Deadline 10 Nov · 82 days left
Conclusion of non-exclusive discount agreements pursuant to § 130 a para. 8 SGB V with the active ingredient combination Adapalene + Benzoyl Peroxide
Deadline 10 Nov · 82 days left
Germany – Medicinal Products – Conclusion of Non-Exclusive Rebate Agreements pursuant to § 130 a para. 8 SGB V with the Active Ingredient Glatiramer Acetate
Deadline 10 Nov · 82 days left
Germany – Pharmaceuticals – Conclusion of non-exclusive rebate agreements pursuant to § 130 a para. 8 SGB V with the active ingredient Aflibercept in the strength 40mg/ml
Deadline 10 Nov · 82 days left
Conclusion of non-exclusive discount agreements pursuant to § 130 a (8) SGB V for contracts of biosimilar active substances
Deadline 10 Nov · 82 days left
Conclusion of non-exclusive rebate agreements pursuant to § 130 a (8) SGB V with the active ingredient glatiramer acetate
Deadline 10 Nov · 82 days left
Conclusion of non-exclusive discount agreements pursuant to § 130 a para. 8 SGB V in the period from 01.05.2025 to 31.12.2026
Deadline 10 Nov · 82 days left
Conclusion of non-exclusive discount agreements pursuant to § 130 a (8) SGB V from 01.07.2025
Deadline 10 Nov · 82 days left
Germany – Pharmaceuticals – Conclusion of non-exclusive discount agreements pursuant to § 130 a para. 8 SGB V with the active ingredient mycophenolic acid in the dosage form PSE.
Deadline 10 Nov · 82 days left
Conclusion of non-exclusive discount agreements pursuant to § 130a (8) SGB V from 01.07.2025
Deadline 10 Nov · 82 days left
Germany – Pharmaceuticals – Conclusion of non-exclusive rebate agreements pursuant to § 130 a para. 8 SGB V with the active ingredient Adalimumab
Deadline 10 Nov · 82 days left
Conclusion of non-exclusive discount agreements pursuant to § 130 a (8) SGB V with the active substance Aflibercept in the strength 40mg/ml
Deadline 10 Nov · 82 days left
Germany – Pharmaceuticals – Conclusion of non-exclusive rebate agreements pursuant to § 130 a para. 8 SGB V for biosimilar active substance contracts
Deadline 10 Nov · 82 days left
Germany – Pharmaceuticals – Conclusion of non-exclusive discount agreements pursuant to § 130 a para. 8 SGB V in the period from 01.05.2025 to 31.12.2026
Deadline 10 Nov · 82 days left
Conclusion of non-exclusive discount agreements pursuant to § 130 a para. 8 SGB V for the period 01.01.2025 - 31.12.2026
Deadline 10 Nov · 82 days left
Germany – Pharmaceuticals – Conclusion of non-exclusive rebate agreements pursuant to § 130 a para. 8 SGB V from 01.03.2025 to 31.12.2026
Deadline 10 Nov · 82 days left
Conclusion of non-exclusive discount agreements pursuant to § 130 a para. 8 SGB V with the active ingredient mycophenolic acid in the dosage form PSE.
Deadline 10 Nov · 82 days left
Conclusion of non-exclusive discount agreements pursuant to § 130 a (8) SGB V with the active ingredient Oxybutynin in the pharmaceutical form PFT
Deadline 10 Nov · 82 days left
Conclusion of non-exclusive discount agreements pursuant to § 130 a para. 8 SGB V for the period from 01.03.2025 to 31.12.2026
Deadline 10 Nov · 82 days left
Purchasing rhythm
Awards per year — who knows the rhythm prepares before the notice appears.
2018200
2019193
2020259
2021291
2022383
2023428
2024391
2025382
2026173
Who has won here before
| Company | Awards | Period |
|---|---|---|
| Hexal AG · Holzkirchen | 67 | 2011–2026 |
| Aristo Pharma GmbH · Berlin | 54 | 2011–2026 |
| kohlpharma GmbH · Merzig | 54 | 2016–2023 |
| neuraxpharm Arzneimittel GmbH · Langenfeld | 49 | 2011–2026 |
| ratiopharm GmbH | 48 | 2015–2026 |
| Micro Labs GmbH · Frankfurt am Main | 44 | 2016–2026 |
| betapharm Arzneimittel GmbH · Augsburg | 44 | 2011–2026 |
| Zentiva Pharma GmbH · Frankfurt am Main | 42 | 2015–2026 |
| PUREN Pharma GmbH & Co. KG · München | 41 | 2016–2026 |
| axicorp Pharma B.V. · EC Den Haag | 41 | 2018–2023 |
From 13.7M documented awards · regular winners know this buyer's requirements — that is your competition.